US FDA to Review Eli Lilly’s Donanemab for Early Alzheimer’s Treatment
The meeting is set to be held on June 10, 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Alzheimer’s disease treatments
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective 1st…